Market Newsdesk

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) — Our Bond, Inc. (“Bond”) (NASDAQ: OBAI), the creator of the world’s first AI-powered Preventative Personal Security platform adopted by leading multinational companies, today announced that a major international city is expanding its relationship with the Company by awarding Bond a deal to provide preventative personal security services for all municipal employees following the successful completion of a pilot program.

The expansion marks another significant milestone in Bond’s rapidly growing business-to-government channel and further validates the Company’s ability to scale from pilot engagements to citywide deployments. The agreement, which Bond expects to be signed imminently as all major points have been agreed, will add to a growing roster of municipal partnerships and highlights increasing demand among cities seeking innovative, technology-driven approaches to improve personal safety and wellbeing for employees and residents alike.

Importantly, Bond and city officials are engaged in ongoing discussions regarding a potential future expansion of services beyond municipal employees to include the city’s entire population of more than 1 million residents, representing a substantial opportunity to deepen the relationship and expand platform adoption and annual recurring revenue.

Bond was once again recognized as a sole supplier in the procurement process, significantly accelerating the sales cycle and reinforcing the differentiated nature of the Company’s offering.

“We believe this expansion further demonstrates the growing momentum we are seeing within the municipal market,” said Doron Kempel, Founder and CEO of Bond. “The city initially engaged Bond through a pilot program, is expanding to all municipal employees after experiencing the value of our platform, and is also exploring the possibility of extending coverage to all residents. We believe this progression validates our land-and-expand strategy and illustrates the significant long-term opportunity for Bond to become a trusted preventative personal security partner for cities around the world.”

The agreement further strengthens Bond’s business-to-government channel, which complements the Company’s direct-to-consumer, business-to-business, and business-to-business-to-consumer offerings.

About Bond

Bond is an international company headquartered in New York City — with command centers around the world — that is redefining personal security through its AI-powered Preventative Personal Security platform. The company has invested more than $100 million to date in its technology, operations, and global expansion.

Bond is trusted by leading corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions. Bond operates in 28 countries and growing, positioning itself as a new global standard for personal security and peace of mind. Additional information about the Company is available at: www.ourbond.com.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading “Risk Factors” in our most recent Registration Statement on Form S-1, under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K, or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, copies of which are available on the SEC’s website at www.sec.gov. Our Bond, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise that occur after the date of this release, except as required by law.

Contact:

Crescendo Communications, LLC
212-671-1020
[email protected]

• First and only oral carbapenem antibiotic approved in the US
• Approval based on PIVOT-PO trial
  demonstrating non-inferiority compared to intravenous treatmentⁱ
• More than 3 million cases of cUTIs are treated annually in the US
  with a third of patients impacted by resistant infections^ii,iii

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis¹, caused by certain susceptible pathogens² in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK’s development and exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.^iv

There are more than 3 million cases of cUTI in the US annually and treatment failure impacts up to 34% of patients.^2,3 Often caused by multidrug-resistant pathogens,^v these infections account for over $6 billion per year in healthcare costs.³ Carbapenems are the standard treatment for severe or resistant infections, but until now have only been available through intravenous administration^vi, increasing hospital resource use and reducing patients’ quality of life.^vii Tebipenem pivoxil offers the potential for an effective oral alternative taken outside of a hospital setting.

Tony Wood, Chief Scientific Officer, GSK, said: “With antibiotic resistance continuing to rise, patients and healthcare professionals need new treatment options. The approval of Utebzi provides the first and only oral carbapenem antibiotic for appropriate adults with complicated UTIs, a solution that could help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections.”

Dr. Bilal Chughtai, Chief of Urology at Plainview Hospital, Northwell Health and Associate Professor of Urology at the Zucker School of Medicine at Hofstra/Northwell, said: “For patients with complicated urinary tract infections (cUTIs) and their caregivers, this approval is a major milestone as today’s standard of care places a serious burden on them and hospitals. A new effective oral treatment offering an alternative option to intravenous care has the potential to enable more treatment in the outpatient settings with the ambition to improve their experience.”

Esther Rajavelu, President and Chief Executive Officer, Spero Therapeutics added: “The FDA approval of tebipenem pivoxil marks the culmination of more than a decade of dedication from our team, partners, and, most importantly, the patients who placed their trust in this program. We are proud to reach this important milestone. Through our partnership with GSK, we look forward to this much-needed oral treatment option reaching cUTI patients to help reduce the burden of the disease.”

This approval is supported by positive results from the PIVOT-PO phase III trial, which demonstrated non-inferiority of tebipenem pivoxil compared to intravenous imipenem-cilastatin in hospitalized patients with cUTI, including pyelonephritis, based on the overall response (composite of clinical cure plus microbiological eradication) at the test of cure visit. Tebipenem pivoxil (oral, 600 mg) achieved a 58.5% overall success rate (261/446 participants) compared to 60.2% overall success rate (291/483 participants) for imipenem-cilastatin (intravenous, 500 mg) (adjusted treatment difference: −1.3%; 95% CI: −7.5%, 4.8%). 

The safety profile of tebipenem pivoxil was generally similar to that of imipenem-cilastatin and other carbapenem antibiotics. The most frequently reported adverse events (in ≥3% of patients) were diarrhoea and headache; these events were all mild or moderate and non-serious.^viii

Tebipenem pivoxil is anticipated to be made available to US patients by the end of 2026. 

This approval confirms the successful and productive collaboration between GSK and Spero Therapeutics. The development of tebipenem pivoxil has been supported in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201800015C and HHSO100201300011C.

About tebipenem pivoxil

Tebipenem pivoxil was developed in collaboration with Spero Therapeutics^ix for the treatment of cUTIs, including pyelonephritis. In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics for the development and commercialization in all markets, except certain Asian territories. Under this agreement, GSK sub-licensed back to Spero Therapeutics the rights and responsibility to conduct certain development work, including the PIVOT-PO phase III study. The sponsorship of the New Drug Application has been transferred to GSK. As part of the license agreement, tebipenem pivoxil has received Qualified Infectious Disease Product and Fast Track designations from the US FDA. 

The US Prescribing Information will be available here [https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Utebzi/pdf/UTEBZI-PI-PIL.PDF]

About the PIVOT-PO trial 

The PIVOT-PO trial was a global, randomized, double-blind, pivotal, non-inferiority (NI margin: -10%) phase III trial evaluating the potential of oral tebipenem pivoxil compared to IV imipenem-cilastatin, in hospitalized adult patients with complicated urinary tract infections, including acute pyelonephritis. Patients were randomized 1:1 to receive tebipenem pivoxil (600 mg) orally every six hours, or imipenem-cilastatin (500 mg) IV every six hours, for a total of seven to ten days. Dose adjustments were made for patients with reduced renal function. Matching placebos were used to maintain blinding. The primary efficacy endpoint was composite response (combined per-patient clinical cure and microbiological response) at the test-of-cure visit (about 17 days from first dose administration of study drug) in patients with qualifying pathogens susceptible to imipenem. The trial enrolled a total of 1,690 patients, with randomization stratified by age, baseline diagnosis (cUTI or acute pyelonephritis), and the presence or absence of urinary tract instrumentation. For further details on the trial, refer to clinicaltrials.gov identifier NCT06059846.^x

About complicated urinary tract infections (cUTIs)

cUTIs are broadly described as any UTI that carries an increased risk of morbidity and mortality.⁵ Definitions of cUTIs are not currently uniform among international societies and regulatory agencies. cUTIs encompass a heterogeneous patient population due to the wide range of host factors, comorbidities and urological abnormalities associated with cUTIs. Risk factors for cUTIs include indwelling catheters, ureteric stents, neurogenic bladder, obstructive uropathy, urinary retention, urinary diversion, kidney stones, diabetes mellitus, immune deficiency, urinary tract modification and UTIs in renal transplant patients.^{xi,xii,xiii,xiv}

About GSK

GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at gsk.com.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential Utebzi to meaningfully improve treatment options for cUTI patients; the potential of Utebzi to help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections; the potential of Utebzi to enable more treatment options in outpatient settings with the ambition to improve patients’ experience; the potential of tebipenem HBr to set a new standard of care and decrease the disease burden. In some cases, forward-looking statements may be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including, but not limited to, whether Spero and GSK will successfully perform their respective obligations under the collaboration between Spero and GSK; risks and uncertainties related to the successful commercial launch of Utebzi and market acceptance; the competitive landscape for Utebzi, risks related to Spero’s expectations regarding the potential clinical benefit of Utebzi to patients; the risk that any regulatory approval may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; the uncertainties inherent in research and development, including clinical results; regulatory actions or delays or government regulation generally; Spero’s ability to protect its intellectual property portfolio; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates; Spero’s reliance on GSK, pursuant to the exclusive GSK License Agreement, to advance development of tebipenem pivoxil and GSK’s right thereunder to determine, in its sole discretion, whether to further develop and commercialize tebipenem pivoxil; Spero’s need for additional funding; Spero’s ability to retain key personnel; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.

Investor Relations Contact:

Shai Biran, PhD
Spero Therapeutics
[email protected]

Media Inquiries:

[email protected]

¹ Pyelonephritis is a specific type of UTI that has travelled up the urinary tract to infect one or both kidneys.

²
Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis. 

ⁱ GSK press release, “Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)”, October 2025. Available at: press-release-tebi-pivot-po-phase-iii-read-out.pdf (last accessed: May 2026)

ⁱⁱ Carreno JJ, et al. “Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection” in Open Forum Infect Dis. 2019;7:ofil446. doi: 10.1093/ofid/ofz446

ⁱⁱⁱ Lodise TP, et al. Hospital admission patterns of adult patients with complicated urinary tract infections who present to the hospital by disease acuity and comorbid conditions: How many admissions are potentially avoidable? Am J Infect Control. 2021;49(12):1528-1534.

^iv GSK press release, GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections, 22 September 2022

^v Sabih A, Leslie SW. “Complicated urinary tract infections” in StatPearls. 2023. StatPearls Publishing: Treasure Island, FL, USA.

^vi Eckburg PB, et al. “Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection”. In New England Journal of Medicine,. 2022;386:1327-1338. doi: 10.1056/NEJMoa2105462

^vii NHS. Reducing complications with a prolonged hospital stay. 2024. Available from: https://www.plymouthhospitals.nhs.uk/display-pil/pil-reducing-complications-with-a-prolonged-hospital-stay-6686 (last accessed: May 2026)

^viii GSK press release, Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs), October 2025

^ix GSK press release, GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections, 22 September 2022

^x CT.gov, A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (PIVOT-PO), last updated on 01 July 2025

^xi Bonkat G, et al. “Keep it Simple: A Proposal for a New Definition of Uncomplicated and Complicated Urinary Tract Infections from the EAU Urological Infections Guidelines Panel”. Eur Urol. 2024;86(3):195-197.

^xii Wagenlehner FME, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nat Rev Urol. 2020;17(10):586-600.

^xiii Gomila A, et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalized patients with complicated urinary tract infections. Antimicrob Resist Infect Control. 2018;7:111.

^xiv Altunal N, et al. Ureteral stent infections: a prospective study. Braz J Infect Dis. 2017;21(3):361-364.

EATONTOWN, N.J., June 17, 2026 (GLOBE NEWSWIRE) — Climb, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) today announced a new distribution partnership with Ivanti, a global enterprise IT and security software company. Through this partnership, Climb will help drive growth and scale operations for Ivanti, while enabling channel partners to deliver more efficient and scalable endpoint operations and expand access to Autonomous Endpoint Management, powered by Ivanti Neurons.

When endpoint data is fragmented across tools, even routine issues can take longer to resolve, slowing operations, increasing risk and limiting an organization’s ability to scale. Ivanti’s Autonomous Endpoint Management solution helps organizations move from reactive support to more proactive, governed operations. Built on the Ivanti Neurons platform, it establishes a trusted system of record across IT and security and brings together Unified Endpoint Management, Digital Experience Management and Endpoint Security capabilities on a single, intelligent platform featuring:

• A system of record that provides a single source of truth across IT and Security
• A unified agentic AI framework that embeds intelligence to drive faster, more informed decision-making
• AI-driven automation to proactively identify, prioritize and resolve issues before they impact users’ productivity and the business as a whole

Together, this approach enables organizations to operate more efficiently, reduce risk and scale with confidence in an increasingly complex endpoint environment. For partners, this creates a stronger opportunity to deliver repeatable, high-value services, across assessment, implementation, automation, optimization and ongoing customer success. With Climb’s distribution reach, more value-added resellers and managed service providers will be able to bring these capabilities to market and expand customer conversations beyond standalone tools to broader endpoint and operational outcomes.

“Our partnership with Climb is a strategic step forward in how we will deliver Autonomous Endpoint Management to customers,” said Michael Mills, Chief Revenue Officer at Ivanti. “Climb’s ability to engage the right partners and support go-to-market efforts, combined with its partner-first approach, makes it well positioned to expand access to Ivanti solutions across the channel. As demand continues to grow, this collaboration will help connect partners with more opportunities to deliver value to customers.”

This strategic partnership signifies a significant addition to Climb’s cybersecurity portfolio and represents a powerful opportunity for its reseller ecosystem. Ivanti’s Autonomous Endpoint Management solution, which helps organizations move from reactive support to more proactive, will now be available to Climb’s partners, and enable them to capitalize on the opportunities the endpoint management market is currently providing.

Dale Foster, CEO, Climb commented on the partnership: “We’re incredibly excited to welcome Ivanti and look forward to working closely with their teams to drive growth and scale across North America. As channel demand for solutions that empower IT and security teams to enhance operational efficiency, cut costs and proactively mitigate security risks, our partnership with Ivanti couldn’t be timelier. Ivanti is a strategic addition to our cybersecurity portfolio, and we’re excited to take their presence in the market to a new level.”

Those interested in distribution services and solutions should contact Climb by phone at +1.800.847.7078 (US), or +1.888.523.7777 (Canada), or by email at [email protected].

About Climb

Climb is a global specialty technology distributor focusing on Security, Data Management, Connectivity, Storage & HCI, Virtualization & Cloud, and Software & Application Lifecycle.  Climb is committed to transforming distribution by providing emerging and established IT technologies, flexible financing, real-time quoting, best of breed channel operations, speed to market, and exceptional service to our partners worldwide. Climb is a wholly owned subsidiary of Climb Global Solutions (NASDAQ: CLMB). Experience the Climb difference and learn how our people first approach empowers VARs and MSPs to grow, scale, and accelerate their business.  Visit www.ClimbCS.com, call 1-800-847-7078, and connect with us on LinkedIn!

For Media & PR inquiries contact:
Climb
Media Relations
[email protected]

Investor Relations Contact:

Elevate IR
Sean Mansouri, CFA
T: 720-330-2829
[email protected]

About Ivanti

Ivanti is a global enterprise IT and security software company dedicated to unlocking human potential by managing, automating and protecting data and systems to empower continuous innovation. With adaptable software solutions tailored to customer needs, Ivanti empowers IT and security teams to enhance operational efficiency, cut costs and proactively mitigate security risks. At the heart of Ivanti’s offerings is the AI-powered Ivanti Neurons platform, which transforms the way IT and security teams operate. By delivering unified, reusable services and tools, the platform helps ensure consistent visibility, scalability, and secure solution implementation, enabling teams to work smarter, not harder. Ivanti follows “Secure by Design” principles to provide software solutions that scale with our customers’ needs to help enable IT and Security to improve operational efficiency while reducing costs and proactively reducing risk. Ivanti fosters an inclusive environment where diverse perspectives are honored and valued, reflecting a commitment to a sustainable future for customers, partners, employees and the planet. Learn more at www.ivanti.com and follow us on social media @GoIvanti.

Visit this page to learn more about Autonomous Endpoint Management solutions.

For more information on Ivanti’s Partner Program, visit here.

SANTA CLARA, Calif., June 17, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes today announced 3131 Camino in Santa Clara, California, will host its highly anticipated Model Grand Opening event on Saturday, June 20 from 11 a.m. to 2 p.m. Home shoppers are invited to tour the stunning new model home located at 3089 El Camino Real in Santa Clara.

Situated in the heart of Santa Clara, 3131 Camino offers an exclusive collection of just 60 townhome and villa-style condos with up to 4-story home designs. These homes feature open floor plans with 2 to 3 bedrooms, 2 to 3 bathrooms, private 1- to 2-car garages, and rooftop terraces available on select homes. Pricing begins at $1.35 million.

“3131 Camino represents the epitome of modern luxury living in one of the most desirable locations in Santa Clara,” said Alli Sweeney, Division President of Toll Brothers in Northern California. “We invite home shoppers to tour our brand-new model home and get inspired by the exceptional architectural designs and personalization opportunities available in this vibrant community.”

Located close to Silicon Valley’s top employers, 3131 Camino offers easy access to Lawrence Caltrain and major thoroughfares, connecting residents to the greater San Francisco Bay Area. The community is surrounded by everyday conveniences, diverse restaurants, and outdoor recreation. Residents also benefit from proximity to Cupertino, Santana Row, downtown San Jose, Stanford Shopping Center, and Mountain View.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

For more information on 3131 Camino or to RSVP for the grand opening event, call 844-790-5263 or visit TollBrothers.com/CA.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies^®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/5aceb61a-e3a8-4e11-a238-d40a6bc335af

https://www.globenewswire.com/NewsRoom/AttachmentNg/3f96fc1f-257d-45dd-8cc4-1b9206d43a18

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)